Clinical Trials in Follow-Up

  • APEX KODIAK SCIENCES

Pathology: Macular Edema Secondary to Inflammation

Description: An open-label, multicenter platform study on the safety, tolerability, bioactivity, and pharmacokinetics of multiple intravitreal therapies in retinal diseases

 

  • ATMOSPHERE

Pathology: Pseudophakic with nAMD

Description: A Randomized, Partially Masked, Controlled, Phase 2b/3 Clinical Study to Evaluate the Efficacy and Safety of RGX-314 Gene Therapy in Participants with nAMD

 

  • EDIC

 Pathology: Diabetic Retina Diseases

Description: Epidemiology of Diabetes Interventions and Complications currently in year 30 of the trial

  • EYEPOINT/LUGANO

Pathology: nAMD

Description: A pivotal phase 3study evaluation the sustained-release therapy DURAVYU (vorolanib) for wet age-related macular degeneration

  • JANSSEN GENE THERAPY TRIAL

Pathology: Geographic Atrophy (GA)

Description: A Phase 2/3, Randomized, Double-masked, Multicenter, Dose-ranging, Sham-controlled Clinical Trial to Evaluate Intravitreal JNJ-81201887 (AAVCAGsCD59) Compared to Sham Procedure for the Treatment of Geographic Atrophy (GA) Secondary to Age-related Macular Degeneration (AMD).

 

  • JANSSEN EXTENSION

Pathology: Geographic Atrophy

Description: Long-term extension study of participants with geographic atrophy (GA) secondary to age-related macular degeneration (AMD) in JNJ-81201887 parent clinical studies. Protocol 81201887MDG3002; Phase 2b

 

  • OCU410-101 (GENE THERAPY)

Pathology: Geographic Atrophy

Description: A phase I/II study to assess the safety and efficacy of OCU410 for geographic atrophy secondary to dry age-related macular degeneration

  • OCULIS STAGE 2

Pathology: Diabetic Macular Edema

Description: A phase 2/3 double-masked, randomized, 2 stage, multicenter study of the efficacy and safety of OCS01 eye drops in subjects with diabetic macular edema

 

  • OTC-TKI-2023-AMD-301, OTX-TKI-2023-AMD-303/SOL-R, SOL-1

Pathology: nAMD

Description: A phase 3, multicenter, double-masked, randomized, parallel-group study to evaluate the efficacy and safety of intravitreal OTX-TKI (axitinib implant) in subjects with neovascular age-related macular degeneration

 

  • PORTAL

Pathology: nAMD

Description: A Multicenter, Open-Label Extension Study to Evaluate the Long-Term Safety and Tolerability of the Port Delivery System with Ranibizumab in Patients with Neovascular Age-Related Macular Degeneration (Portal).